DE60325717D1 - Verfahren zur behandlung von angststörungen bei älteren personen - Google Patents
Verfahren zur behandlung von angststörungen bei älteren personenInfo
- Publication number
- DE60325717D1 DE60325717D1 DE60325717T DE60325717T DE60325717D1 DE 60325717 D1 DE60325717 D1 DE 60325717D1 DE 60325717 T DE60325717 T DE 60325717T DE 60325717 T DE60325717 T DE 60325717T DE 60325717 D1 DE60325717 D1 DE 60325717D1
- Authority
- DE
- Germany
- Prior art keywords
- appearance
- treatment
- elderly persons
- anxiety
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37546202P | 2002-04-25 | 2002-04-25 | |
| PCT/US2003/010473 WO2003090772A1 (en) | 2002-04-25 | 2003-04-17 | Method for treating anxiety and mood disorders in older subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60325717D1 true DE60325717D1 (de) | 2009-02-26 |
Family
ID=29270644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60325717T Revoked DE60325717D1 (de) | 2002-04-25 | 2003-04-17 | Verfahren zur behandlung von angststörungen bei älteren personen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129691A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1501531B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005523335A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE419871T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003223474B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2483729A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60325717D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2318123T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003090772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2344645T3 (es) | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| AU2005290250A1 (en) * | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US20060153772A1 (en) * | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| PE20061323A1 (es) * | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| NZ568012A (en) * | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| RU2498999C2 (ru) * | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| HRP20150086T1 (xx) * | 2007-06-12 | 2015-02-27 | Ac Immune S.A. | Humanizirana antitijela za beta amiloid |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PL2238166T3 (pl) * | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| JP5249482B2 (ja) * | 1999-06-16 | 2013-07-31 | ボストン・バイオメデイカル・リサーチ・インステイテユート | インビボのβ−アミロイドレベルの免疫学的制御 |
| EA006606B1 (ru) * | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| US7166478B2 (en) * | 2002-03-12 | 2007-01-23 | Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. | Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses |
-
2003
- 2003-04-17 ES ES03719604T patent/ES2318123T3/es not_active Expired - Lifetime
- 2003-04-17 EP EP03719604A patent/EP1501531B1/en not_active Revoked
- 2003-04-17 JP JP2003587405A patent/JP2005523335A/ja not_active Ceased
- 2003-04-17 WO PCT/US2003/010473 patent/WO2003090772A1/en not_active Ceased
- 2003-04-17 AT AT03719604T patent/ATE419871T1/de not_active IP Right Cessation
- 2003-04-17 DE DE60325717T patent/DE60325717D1/de not_active Revoked
- 2003-04-17 AU AU2003223474A patent/AU2003223474B2/en not_active Ceased
- 2003-04-17 US US10/512,527 patent/US20050129691A1/en not_active Abandoned
- 2003-04-17 CA CA002483729A patent/CA2483729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE419871T1 (de) | 2009-01-15 |
| WO2003090772A1 (en) | 2003-11-06 |
| CA2483729A1 (en) | 2003-11-06 |
| EP1501531A1 (en) | 2005-02-02 |
| AU2003223474B2 (en) | 2008-09-04 |
| US20050129691A1 (en) | 2005-06-16 |
| AU2003223474A1 (en) | 2003-11-10 |
| EP1501531A4 (en) | 2006-02-15 |
| EP1501531B1 (en) | 2009-01-07 |
| ES2318123T3 (es) | 2009-05-01 |
| JP2005523335A (ja) | 2005-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE419871T1 (de) | Verfahren zur behandlung von angststörungen bei älteren personen | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| ATE401395T1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
| EP1701664A4 (en) | SYSTEM AND METHOD FOR PROCESSING A FABRIC | |
| EP1572075A4 (en) | METHOD OF TREATING DISEASES ASSOCIATED WITH ABNORMAL KINASE ACTIVITY | |
| DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
| DE60320007D1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| DE60324777D1 (de) | Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten | |
| ATE527016T1 (de) | System zur überwachung oder behandlung von erkrankungen des nervensystems | |
| ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| DE60312505D1 (de) | Injektion aus ixeris sonchifolia zur behandlung von kardiozerebralen gefässerkrankungen und funduserkrankungen sowie herstellungsverfahren dafür | |
| DE602004001134D1 (de) | Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| EP1592464A4 (en) | METHOD FOR THE TREATMENT OF COGNITIVE EXPOSURE TO SLEEP LEAVES AND STRESS | |
| DE60224004D1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE470453T1 (de) | Verfahren zur behandlung von atherosklerose | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| ATE287713T1 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
| DE60120961D1 (de) | Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen | |
| EP1476440A4 (en) | METHODS AND COMPOUNDS USEFUL IN INHIBITION BY RADICAL AND / OR OXIDIZING AGGRESSION AND IN THE TREATMENT AND PREVENTION OF DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8331 | Complete revocation | ||
| R082 | Change of representative |
Ref document number: 1501531 Country of ref document: EP Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE |